Industry is increasingly exploring the use of AI chatbots to potentially diagnose and treat various medical conditions, including in the area of mental health. FDA is just beginning to develop its regulatory framework for approved, cleared, or authorized devices in the mental health space based on generative AI technology. The medtech industry, healthcare providers, and
Latest Post
More Posts
The Union of AI and Drug Discovery and Development Requires New Thinking for Structuring and Negotiating Strategic Transactions, and a Rigorous Analysis of Applicable Regulatory Considerations
The AI Revolution and the FDA: Becky Wood and Deeona Gaskin’s Fireside Chat with Former FDA Commissioner Dr. Scott Gottlieb
HHS-OIG Rejects Calls for New Safe Harbors for Financial Support to Patients Enrolled in Clinical Trials
Digital Health and Artificial Intelligence: New Developments From President Biden’s Executive Order
EU, U.S., and UK Regulatory Developments on the Use of Artificial Intelligence in the Drug Lifecycle
Five Tips for Bringing a Complex Digital Health Product to Market
Clinical Decision Support Software Approach Updated in the U.S. but Still Confused in Europe
Subscribe: Subscribe via RSS
Blogs
Firm/Org